- Home
- IXHL vs CUE Comparison
IXHL vs CUE Comparison
Compare IXHL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IXHL | CUE |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 27.1M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IXHL | CUE |
|---|---|---|
| Price | $3.97 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 6.3M | 366.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | $12,000.00 | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.11 | $0.23 |
| 52 Week High | $5.17 | $1.21 |
Technical Indicators
Market Signals| Indicator | IXHL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 89.14 | 39.68 |
| Support Level | $0.32 | $0.28 |
| Resistance Level | N/A | $0.36 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.39 | 0.00 |
| Stochastic Oscillator | 76.27 | 25.81 |
Price Performance
Historical ComparisonAbout IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.